ITMI20120354A1 - Processo per la produzione di aliskirene - Google Patents
Processo per la produzione di aliskirene Download PDFInfo
- Publication number
- ITMI20120354A1 ITMI20120354A1 IT000354A ITMI20120354A ITMI20120354A1 IT MI20120354 A1 ITMI20120354 A1 IT MI20120354A1 IT 000354 A IT000354 A IT 000354A IT MI20120354 A ITMI20120354 A IT MI20120354A IT MI20120354 A1 ITMI20120354 A1 IT MI20120354A1
- Authority
- IT
- Italy
- Prior art keywords
- compound
- scheme
- isolated
- added
- moles
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 21
- 229940125773 compound 10 Drugs 0.000 claims description 4
- 229940125782 compound 2 Drugs 0.000 claims description 4
- 229940126214 compound 3 Drugs 0.000 claims description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 4
- 229940125898 compound 5 Drugs 0.000 claims description 3
- KLRSDBSKUSSCGU-KRQUFFFQSA-N aliskiren fumarate Chemical compound OC(=O)\C=C\C(O)=O.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC KLRSDBSKUSSCGU-KRQUFFFQSA-N 0.000 claims description 2
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims 1
- 229960004601 aliskiren Drugs 0.000 claims 1
- 229960004863 aliskiren hemifumarate Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
- 102100028255 Renin Human genes 0.000 description 4
- 108090000783 Renin Proteins 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- -1 THF compound Chemical class 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N delta-valerolactam Natural products O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 150000003954 δ-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
PROCESSO PER LA PRODUZIONE DI ALISKIRENE
Introduzione
Il sistema renina-angiotensina (RAS) gioca un ruolo centrale nella regolazione della pressione sanguinea cosi come nel mantenere il bilanciamento del sodio e degli elettroliti.
L’intervento in questa cascata è stato studiato come possibile opportunità per il trattamento dell’ipertensione e per le insufficienze cardiache. Dato che l’attività del RAS avviene attraverso due eventi enzimatici mediati rispettivamente dalla renina (che funziona come first rate-limiting step) e dall’enzima convertitore dell’angiotensina (ACE), si può certamente dedurre che l’inibizione di renina e ACE può avere effetti sull’ipertensione. Considerato che l’angiotensinogeno è l’unico substrato naturale conosciuto per la renina, mentre oggi si conoscono numerosi substrati per l’ACE, è stata individuata la renina come target ideale per 10 sviluppo di un farmaco anti-ipertensivo.
Aliskirene (conosciuto anche come CGP 60536B e SPP-100B) è il primo inibitore della renina non-peptidico orale identificato dopo molti anni di ricerche.
A causa dell’interesse dal punto di vista della sua attività biologica e della complessità strutturale, recentemente sono stati pubblicati diversi articoli e brevetti che descrivono possibili sintesi dell’Aliskirene.
L’interesse per questo composto è legato anche alla difficoltà di applicare una via di sintesi che permette di ottenere buone rese su scala industriale e una qualità elevata per l’utilizzo in campo farmaceutico.
Sorprendentemente la sintesi rivendicata nel presente brevetto, si è rivelata applicabile su scala industriale e permette di ottenere l’ Aliskirene con buone rese e elevata purezza.
11 brevetto tiene in considerazione i seguenti documenti già depositati:
US 5,559,111, EP 0,678,503, US 6,800,769. EP 2,062,874, EP 2,189,402, US 5,627,182. US 5,705,658, WO 2010 10165, WO 2007 123718, WO 2006 83924
e le pubblicazioni: J.Org. Chem. 1987, 52, 2615, Tetrah. Lett. 2004, 5355, J. Org. Chem.
2006, 71, 3804 and 4766, Org. Lett. 2005, 7, 3653, Tetrahedron 2007, 63, 5639, Tetrah. Lett.
1991, 32, 3623, Tetrah. Lett. 2005,46, 6337, Helv. Chim. Acta 2003, 86, 2848, J.Org. Chem.
2002, 67, 4261, J. Med. Chem. 2007, 50,4832, Ann. Report Med. Chem.2009, 44, 105, Bioorg. Med. Chem. Lett. 2009, 19, 4863, Bioorg. Med. Chem. Lett. 2010, 20, 694, Chirality 2000, 12, 404, Drug of thè Future 2001, 26, 1139, J. Am. Chem. Soc. 1983, 105, 4499, Org. Lett. 2001, 3, 2201, J. Am. Chem. Soc. 1987, 52, 2615
Descrizione dell’invenzione
La sintesi segue le reazioni riportate nello Schema 1.
Scheme 1.
Il composto (1) si ottiene secondo la sintesi descritta in Helv. Chim. Acta. Questo intermedio viene trattato con TrCl in NEt3e CHC13per ottenere (2). Il prodotto (21 trattato con LiCH2PO(OCH3)2 in THF porta all’ottenimento di (3), che per reazione con (CH3)2-CH-CO COOMe e NaH a 0° in THF genera il composto (4). Per reazione di (4) con LiOH in H20, MeOH e THF si isola il composto (5). Con il trattamento di (5) con N-idrossisuccinimmide in DCC e THF si ottiene intermedio (6) che in Et20 e HC1 genera (7). La riduzione di (7) con L-Selectride® a -78° porta all’isolamento di (8). Il composto (8) viene ulteriormente ridotto per idrogenazione con Pd/C in acetato di etile a dare (9). Il trattamento di (9) con HC1 a riflusso genera (10). L’intermedio (10) viene trattato con NH2-CH2-C(CH3)2-CO-NH2in TEA a 90° per 16 ha dare (11) il quale in presenza di acido fumarico genera TAliskiren emifumarato in alte rese (71%).
Esempi
Composto 1
Il composto 1 viene isolato secondo la metodologia descritta in Helvetica Chimica Acta [ voi.
86; pagine 2848-2870 - (2003)] in 6 passaggi con una resa totale del 75%.
'H-NMR: 6.65- 6.80 (m-3H); 4.10 (t, J=7, 2H); 3.83 (s, 3H); 3,67 (s, 3H); 3.57 (t, J=7, 2H); 3.34 (s, 3H); 3.32 (m, IH); 2.50 (m, 2H); 2.10 (m, 2H); 1.75 (m, 2H); 1.2-1.65 (m, 4H); 0.86 (m, 6H).
Composto 2
Ad una soluzione di Composto 1 (2 moli) in CHCL (0.5M), si aggiunge Trietilammina ( 1,1 mole) quindi (Ph)3Cl (2.5 moli, conc. 10%) si lascia reagire per 10 h at r.t. per dare il composto 2 (resa: 92%). La miscela di reazione viene trattata due volte con acqua, la fase organica viene evaporata a pressione ridotta fino ad ottenere il residuo grezzo. Il composto 2 viene utilizzato tal quale senza ulteriori purificazioni.
<13>C-NMR: C 148.4; C 147.1; (3 C) 145.0; C 131.5; CH 113.3;^3 CH) 127.0 CH 111.8; CH 121.8; (3CH) 127.0; (6 CH) 129.2; (3 CH) 126.2; C 171.5; CH2 6 5.3CH2 70.9; CH3 56.1; CH3 51.9; CH3 59.3; C 75.5; CH 57.5; CH2 38.4; CH 39.0; CH 31.6; CH2 29.1; CH2 34.1; (2 CH3) 21.0.
Composto 3
Ad una miscela di Litio-metil-dimetossifosfonato (6 moli) in THF a T = -70°C viene aggiunto 2 (2 moli), e la miscela viene fatta reagire per 3 ore. Quindi si porta a T = 0°C e si aggiunge una soluzioni di NH4C1 al 25%. Si aggiunge TBME e si separano le fasi . La fase organica viene seccata a pressione ridotta, il residuo ottenuto viene cristallizzato da una miscela di metanolo / isopropanolo per dare il composto 3 con il 75% di resa.
<13>C-NMR: C 148.4 ; C 147.1; (3 C) 145.0 ; C 131.5; CH 113.3; (3 CH) 127.0; CH 111.8; CH 121.8; (3 CH) 127.0; (6 CH) 129.2; (3 CH) 126.2; CH2 43.5; C 207.1; CH2 65.3; CH2 70.9; (2 CH3) 53.1; CH3 56.1; CH3 59.3 ; C 75.6; CH 69.1; CH2 38.4; CH 39.1; CH 31.6; CH2 29.1; CH2 32.3; (2 CH3) 21.0
Composto 4 e 5
Al composto 3 (2 moli; conc. 10%) in THF ( 0.5M) viene aggiunto NaH at 0°C; dopo la formazione della betaina si aggiunge (CH3)2 -CH-CO-COOMe ( 2,5moli) sempre a 0°C e si lascia reagire per 16 ore circa, fino ad ottenere il composto 4 che non viene isolato. Quindi alla miscela si aggiunge una soluzione di LiOH in acqua/ MeOH. La miscela ottenuta viene fatta reagire a T = 25°C per 12 ore. Al termine viene aggiunta una soluzione NH4C1 al 25%, si separano le fasi, e la fase acquosa viene estratta con 2 volumi di Etile Acetato, per due volte. Le fasi organiche riunite vengono evaporate a pressione ridotta, il residuo viene cristallizzato con 3 volumi (calcolati sul peso iniziale) di TBME, fornendo il composto 5 con il 65% di resa nei due passaggi.
<13>C-NMR: C 148.4; C 147.1; (3 C) 145.0; C 131.5; CH 113.3; (3 CH) 127.0; CH 111.8; CH 121.8; (3 CH) 127.0; (6 CH) 129.2; (3 CH) 126.2; C 171.3; C 197.6; CH2 65.3; CH2 70.9; CH3 56.1; CH3 59.3; C 75.6; CH 65.4; CH2 38.4; C 151.3; CH 131.5; CH 39.1; CH 25.9; CH 31.6; CH2 29.1; CH2 32.6; (2 CH3) 20.9; (2 CH3) 21.0.
Composto 6
Al composto 5 (2 moli; 0.5M) sciolto in THF viene aggiunta DCC ( 2.8moli) , quindi si aggiunge N-idrossisuccinimmide (3 moli) si lascia reagire per 10 ore a T = 25°C. Si filtra il precipitato , la soluzione ottenuta viene evaporata a pressione ridotta, si aggiunge Cloruro di metilene si agita fino ad ottenimento di un precipitato che viene rimosso per filtrazione.
La soluzione ottenuta viene evaporata a pressione ridotta. Il residuo viene precipitato da eptano ottenendo il composto 6 (resa 82%).
<13>C-NMR: (2 C) 169.0; (2 CH2) 25.6; C 148.4; C 147.1; (3 C) 145.0; C 131.5; CH 113.3; (3 CH) 127.0; CH 111.8; CH 121.8; (3 CH) 127.0; (6 CH) 129.2; (3 CH) 126.2; C 177.5; C 207.1; CH2 65.3; CH2 70.9; CH3 56.1; CH3 59.3; C 75.6; CH 67.9; CH2 38.4; C 130.1; C 153.6; CH 39.1; CH 31.6; CH2 36.2; CH2 29.1; CH2 32.7; CH3 21.7; (2 CH3) 21.7; (2 CH3) 21.0
Composti 7 e 8
Il composto 6 (2 moli) sciolto in Acetone , viene trattato HC1 a T = 25°C per 3 ore. Quindi si aggiunge Na2C031M in acqua e si lascia reagire per 4 ore. Si aggiunge TBME e si separano le fasi; la fase organica viene seccata e la soluzione viene evaporata a pressione ridotta. Il composto 7 è stato utilizzato direttamente per la reazione successiva senza isolarlo. Il residuo viene ridisciolto in TBME e, in atmosfera di azoto, viene raffreddato a T = -70°C.si aggiunge L-Selectride ® , si lascia reagire per 3h., quindi alla reazione viene aggiunto NH4C1 soluzione satura. Si separano le fasi; la fase organica viene evaporata a pressione ridotta.
Il residuo è cristallizzato da Etere per ottenere il composto 8 con resa 70%
<l3>C-NMR: C 165.1; C 148.4; C 147.1; CH 70.8; CH 57.6; C 131.5; CH 113.3; CH 111.8; CH
121.8; C 133.3; CH2 34.9; CH2 65.3 ; CH2 70.9; CH3 56.1; CH3 59.3; C 140.8; CH2 30.8;
CH2 38.7; CH 39.6; CH 31.9; CH2 29.1; (3 CH3) 21.6
Composto 9
L’idrogenazione dell’intermedio 8 (idrossi-lattame) (1.5 moli; 5% conc) in EtOAc con Pd/C genera a 20°C il δ-lactam 9 saturo in rese quantitative (98%) come singolo diastereoisomero (98%)..
La stereochimica per queste trasformazioni può essere attribuita all’influenza sierica del sostituente al C-5 della funzione del cheto-lattame.
<13>C-NMR: C 175.0; C 148.4; C 147.1; CH 76.3; CH 57.6; C 131.5; CH 113.3; CH 111.8; CH 121.8; CH 45.1; CH2 38.9; CH2 65.3; CH2 70.9; CH3 56.1; CH3 59.3; CH 27.9; CH2 30.8; CH2 38.7; CH 39.6; CH 31.9; CH2 29.1; (2 CH3) 20.0; (2 CH3) 21.0
Composto 10
Il composto 9 (1.5 moli) viene trattato a riflusso con HC1 6N per 6 h per dare direttamente il lattone 10 con il 94% di resa. La purezza chirale del composto 10 è stata confermata essere > 99% sulla base di analisi NMR e HPLC.
<13>C-NMR: C 179.5; CH 87.4; CH 34.1; CH2 33.5; C 148.4; C 147.1; C 131.5; CH 113.3; CH 111.8; CH 121.8; CH2 65.3; CH2 70.9; CH3 56.1; CH3 59.3; CH 49.8; CH3 16.6; CH2 38.7; CH 39.3; CH 31.9; CH2 29.1; CH2 34.0; (2 CH3) 21.0
AJiskirene
Una miscela di composto 10 (1.5 moli) e 3 amino-2,2-di-metil propionamide (1.5 moli) in idrossipiridina (0.5 moli) in Et3N viene aggiunta sotto agitazione per 16 h a 90°C. Il solvente viene ridotto di volume e la miscela mantenuta a 90°C per altre 10 h. Dopo aver raffreddato la reazione, si aggiunge una soluzione satura di NaHC03e si estrae con acetato di etile per ottenere il composto grezzo. Il sale emifumarato di Aliskirene si ottiene in accordo con la procedura descritta nel brevetto US 6,800,769 con una resa totale del 90%.
Il composto così ottenuto dimostra, oltre ad avere una resa buona su scala industriale, anche una elevata purezza per un successivo utilizzo in terapia
Claims (1)
- Aliskiren preparato su scala industriale in accordo con lo Schema 1 con alte rese e purezza elevata Derivati simili a Aliskiren preparati su scala industriale in accordo allo Schema 1. Composto 2 preparato in accordo allo Schema 1 e isolato in alte rese Composto 3 preparato in accordo allo Schema 1 e isolato in alte rese Composto 4 preparato in accordo allo Schema 1 Composto 5 preparato in accordo allo Schema 1 e isolato in alte rese Composto 6 preparato in accordo allo Schema 1 e isolato in alte rese Composto 7 preparato in accordo allo Schema 1 Composto 8 preparato in accordo allo Schema 1 e isolato in alte rese Composto 9 preparato in accordo allo Schema 1 e isolato in alte rese Composto 10 preparato in accordo allo Schema 1 e isolato in alte rese Aliskiren emifumarato preparato in accordo allo Schema 1 e isolato con alte rese ed elevata purezza.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000354A ITMI20120354A1 (it) | 2012-03-07 | 2012-03-07 | Processo per la produzione di aliskirene |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000354A ITMI20120354A1 (it) | 2012-03-07 | 2012-03-07 | Processo per la produzione di aliskirene |
Publications (1)
Publication Number | Publication Date |
---|---|
ITMI20120354A1 true ITMI20120354A1 (it) | 2013-09-08 |
Family
ID=46727334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT000354A ITMI20120354A1 (it) | 2012-03-07 | 2012-03-07 | Processo per la produzione di aliskirene |
Country Status (1)
Country | Link |
---|---|
IT (1) | ITMI20120354A1 (it) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0678503A1 (de) * | 1994-04-18 | 1995-10-25 | Ciba-Geigy Ag | Delta-Amino-gamma-hydroxy-omega-aryl-alkansäureamide mit Enzym-, insbesondere Renin-hemmenden Eigenschaften |
GB2431649A (en) * | 2005-10-25 | 2007-05-02 | Novartis Ag | Alternative synthesis of aryl-octanoyl amide compounds |
EP1978012A1 (en) * | 2004-08-31 | 2008-10-08 | Novartis AG | Alternative synthesis of renin inhibitors and intermediates thereof |
WO2009064479A1 (en) * | 2007-11-13 | 2009-05-22 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
US20110092706A1 (en) * | 2009-10-21 | 2011-04-21 | CarboDesign LLC | Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren |
US20110244531A1 (en) * | 2008-07-23 | 2011-10-06 | Andreas Hendrikus Maria De Vries | Synthesis routes to 2(s),4(s),5(s),7(s)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides |
-
2012
- 2012-03-07 IT IT000354A patent/ITMI20120354A1/it unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0678503A1 (de) * | 1994-04-18 | 1995-10-25 | Ciba-Geigy Ag | Delta-Amino-gamma-hydroxy-omega-aryl-alkansäureamide mit Enzym-, insbesondere Renin-hemmenden Eigenschaften |
EP1978012A1 (en) * | 2004-08-31 | 2008-10-08 | Novartis AG | Alternative synthesis of renin inhibitors and intermediates thereof |
GB2431649A (en) * | 2005-10-25 | 2007-05-02 | Novartis Ag | Alternative synthesis of aryl-octanoyl amide compounds |
WO2009064479A1 (en) * | 2007-11-13 | 2009-05-22 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
US20110244531A1 (en) * | 2008-07-23 | 2011-10-06 | Andreas Hendrikus Maria De Vries | Synthesis routes to 2(s),4(s),5(s),7(s)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides |
US20110092706A1 (en) * | 2009-10-21 | 2011-04-21 | CarboDesign LLC | Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114057627B (zh) | 一种丙型肝炎及新冠药物中间体及其盐的制备方法 | |
MX2007012446A (es) | Compuestos intermediarios para la preparacion de trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz(2,3:6,7)- oxepino[4,5-c]pirrol. | |
IL95480A (en) | Process for the preparation of cyclic amino acids and intermediates | |
ITMI20101239A1 (it) | Processo ed intermedi per la preparazione di un principio attivo | |
CN107513031A (zh) | 一种2-氧代-1-吡咯烷手性衍生物的制备方法 | |
JP2016537315A (ja) | リン酸オセルタミビル調製用中間体の調製方法 | |
FI90862B (fi) | 2-atsa-4-(alkoksikarbonyyli)spiro/4,5/dekan-3-oni | |
EP2914574A2 (en) | New process | |
EP1833798B1 (en) | A process for the preparation of (s)-(+)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide | |
ITMI20120354A1 (it) | Processo per la produzione di aliskirene | |
CN1194971C (zh) | 2-丁基-1,3-二氮杂螺环[4.4]壬烷-1-烯-4-酮的改进的生产工艺 | |
JP5556811B2 (ja) | テトラヒドロピラン化合物の製造方法 | |
CN113072514B (zh) | 轮环藤宁及其中间体的制备方法 | |
WO2021020998A1 (ru) | Способ получения роксадустата | |
CN110698419A (zh) | 一种轮环藤宁的制备方法 | |
CN101255161B (zh) | 9-pg-3,9-二氮杂-2,4-二氧代-螺[5.5]十一烷的合成方法 | |
EP1732899B1 (en) | Process for preparing cyclohexanediacetic acid monoamide | |
CN110563687B (zh) | 一种4-(氨基甲基)色烷-3-醇的制备方法 | |
KR100856133B1 (ko) | 아토르바스타틴의 개선된 제조방법 | |
US4906759A (en) | Process for the production of 4-alkoxy-2(5H) thiophenones | |
KR100850558B1 (ko) | 아토르바스타틴의 효율적인 제조방법 | |
JP4699582B2 (ja) | 1h−4(5)−アミノイミダゾール−5(4)−カルボキサミドの製造方法 | |
EP1905760B1 (en) | Process for production of optically active aminopentane derivative, intermediate in the process and process for production of the intermediate | |
KR101142052B1 (ko) | 자나미비어의 제조방법 | |
KR100958678B1 (ko) | 시스-디메크로틴산 및 이의 염의 제조방법 |